Barry  Ticho net worth and biography

Barry Ticho Biography and Net Worth

Insider of Stoke Therapeutics
Barry Ticho is the chief medical officer at Stoke Therapeutics, where he is helping to lead the company’s efforts to develop first-in-class therapeutics to treat rare diseases. Prior to joining Stoke, Barry was most recently head of development of mRNA treatments for cardiovascular and metabolic diseases at Moderna Therapeutics. Before Moderna, he was head of external R&D innovation for cardiovascular and metabolic diseases at Pfizer, and before that, he was vice president of clinical development at Biogen. Barry obtained his M.D. and Ph.D. degrees from the University of Chicago. He completed pediatrics training at Northwestern University and a cardiology fellowship at Boston Children’s Hospital. Barry has also served as a member of the clinical staff at Harvard Medical School and Massachusetts General Hospital, where he conducted laboratory research on the regulation of cardiac development.

What is Barry Ticho's net worth?

The estimated net worth of Barry Ticho is at least $98,920.77 as of February 1st, 2024. Dr. Ticho owns 6,981 shares of Stoke Therapeutics stock worth more than $98,921 as of March 28th. This net worth estimate does not reflect any other investments that Dr. Ticho may own. Additionally, Dr. Ticho receives an annual salary of $688,830.00 as Insider at Stoke Therapeutics. Learn More about Barry Ticho's net worth.

How old is Barry Ticho?

Dr. Ticho is currently 63 years old. There are 7 older executives and no younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who is 75 years old. Learn More on Barry Ticho's age.

What is Barry Ticho's salary?

As the Insider of Stoke Therapeutics, Inc., Dr. Ticho earns $688,830.00 per year. The highest earning executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who commands a salary of $931,210.00 per year. Learn More on Barry Ticho's salary.

How do I contact Barry Ticho?

The corporate mailing address for Dr. Ticho and other Stoke Therapeutics executives is 45 WIGGINS AVENUE, BEDFORD MA, 01730. Stoke Therapeutics can also be reached via phone at (781) 430-8200 and via email at [email protected]. Learn More on Barry Ticho's contact information.

Has Barry Ticho been buying or selling shares of Stoke Therapeutics?

During the past quarter, Barry Ticho has sold $105,400.00 of Stoke Therapeutics stock. Most recently, Barry Ticho sold 10,000 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $4.80, for a transaction totalling $48,000.00. Following the completion of the sale, the insider now directly owns 6,981 shares of the company's stock, valued at $33,508.80. Learn More on Barry Ticho's trading history.

Who are Stoke Therapeutics' active insiders?

Stoke Therapeutics' insider roster includes Edward Kaye (), Huw Nash (COO), and Barry Ticho (Insider). Learn More on Stoke Therapeutics' active insiders.

Are insiders buying or selling shares of Stoke Therapeutics?

In the last twelve months, insiders at the sold shares 10 times. They sold a total of 119,227 shares worth more than $1,065,158.12. The most recent insider tranaction occured on March, 19th when CFO Stephen J Tulipano sold 4,116 shares worth more than $25,107.60. Insiders at Stoke Therapeutics own 12.3% of the company. Learn More about insider trades at Stoke Therapeutics.

Information on this page was last updated on 3/19/2024.

Barry Ticho Insider Trading History at Stoke Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2024Sell10,000$4.80$48,000.006,981View SEC Filing Icon  
1/2/2024Sell10,000$5.74$57,400.0016,981View SEC Filing Icon  
7/3/2023Sell15,000$10.60$159,000.0025,895View SEC Filing Icon  
6/1/2023Sell15,000$11.13$166,950.0040,895View SEC Filing Icon  
5/3/2023Sell24,697$10.14$250,427.5856,548View SEC Filing Icon  
5/1/2023Sell24,967$10.00$249,670.0086,758View SEC Filing Icon  
2/6/2023Sell9,235$10.02$92,534.70111,725View SEC Filing Icon  
2/2/2023Sell267$10.00$2,670.00124,723View SEC Filing Icon  
1/31/2023Sell200$10.00$2,000.00130,695View SEC Filing Icon  
7/13/2021Sell43,166$32.75$1,413,686.50View SEC Filing Icon  
12/21/2020Sell1,365$57.62$78,651.30View SEC Filing Icon  
6/1/2020Sell1,365$27.39$37,387.35131,147View SEC Filing Icon  
See Full Table

Barry Ticho Buying and Selling Activity at Stoke Therapeutics

This chart shows Barry Ticho's buying and selling at Stoke Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Stoke Therapeutics Company Overview

Stoke Therapeutics logo
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.
Read More

Today's Range

Now: $14.17
Low: $10.36
High: $16.40

50 Day Range

MA: $5.88
Low: $4.12
High: $10.29

2 Week Range

Now: $14.17
Low: $3.35
High: $16.40

Volume

17,720,633 shs

Average Volume

1,408,220 shs

Market Capitalization

$656.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68